Stay updated on Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page now includes an NIH grant/contract entry for 2018, and the revision tag has been updated from v3.6.5 to v3.6.6.
    Difference
    0.1%
    Check dated 2026-08-30T15:24:14.000Z thumbnail image
  2. Check
    15 days ago
    No Change Detected
  3. Check
    22 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5, indicating a software/documentation update on the page. This change does not alter trial details, eligibility criteria, or results, but reflects an updated version of the page infrastructure.
    Difference
    0.0%
    Check dated 2026-08-08T23:18:42.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The study page now shows a new revision label (v3.6.4), indicating a version update. The rest of the content, including trial details and eligibility information, appears unchanged.
    Difference
    0.0%
    Check dated 2026-07-25T17:13:09.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.2 to v3.6.3 on the page, representing a small metadata update to the page.
    Difference
    0.0%
    Check dated 2026-07-04T13:27:16.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The study page was updated from revision v3.6.0 to v3.6.2, signaling a maintenance update to the page. It does not alter the study details, eligibility criteria, or results.
    Difference
    0.0%
    Check dated 2026-06-27T07:45:48.000Z thumbnail image
  8. Check
    86 days ago
    Change Detected
    Summary
    The page now shows that recruitment is closed, indicating no new participants will be enrolled. This clarifies the study's current status for participants and investigators reviewing eligibility and enrollment options.
    Difference
    0.3%
    Check dated 2026-06-13T05:12:58.000Z thumbnail image

Stay in the know with updates to Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.